Objective: To examine the impact of selective serotonin reuptake inhibitors (SSRIs) and depression on neurogenesis and cognition in dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD). Methods: Late-stage progenitor cells were quantified in the subgranular zone (SGZ) of the hippocampal dentate gyrus of DLB/PDD patients (n = 41) and controls without dementia (n = 15) and compared between treatment groups (unmedicated, SSRIs, acetyl cholinesterase inhibitors [AChEIs], combined SSRIs and AChEIs). Results: DLB/PDD patients had more doublecortin-positive cells in the SGZ compared to controls. The doublecortin-positive cell count was higher in the SGZ of patients treated with SSRIs and correlated to higher cognitive scores. Conclusion: SSRI treatment was associated with increased hippocampal neurogenesis and preservation of cognition in DLB/PDD patients.

Keywords:
Dementia, Neurogenesis, Depression, Selective serotonin reuptake inhibitors, Acetylcholinesterase inhibitors, Cognition, Hippocampus, Post-mortem
1.
McKeith IG, Dickson DW, Lowe J, Emre M, et al: Diagnosis and management of dementia with Lewy bodies - third report of the DLB consortium. Neurology 2005;65:1863-1872.
2.
Walker Z, Possin KL, Boeve BF, Aarsland D: Lewy body dementias. Lancet 2015;386:1683-1697.
3.
Aarsland D, Zaccai J, Brayne C: A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005;20:1255-1263.
4.
Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-2518.
5.
Mori E, Ikeda M, Kosaka K, Donepezil-DLB Study Investigators: Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012;72:41-52.
6.
Pantzar A, Atti AR, Fratiglioni L, Fastbom J, Backman L, Laukka EJ: Cognitive performance in unipolar old-age depression: a longitudinal study. Int J Geriatr Psychiatry 2016;32:675-684.
7.
Baquero M, Martin N: Depressive symptoms in neurodegenerative diseases. World J Clin Cases 2015;3:682-693.
8.
da Silva J, Goncalves-Pereira M, Xavier M, Mukaetova-Ladinska EB: Affective disorders and risk of developing dementia: systematic review. Br J Psychiatry 2013;202:177-186.
9.
Reichmann H, Brandt MD, Klingelhoefer L: The nonmotor features of Parkinson's disease: pathophysiology and management advances. Curr Opin Neurol 2016;29:467-473.
10.
Fritze F, Ehrt U, Hortobagyi T, Ballard C, Aarsland D: Depressive symptoms in Alzheimer's disease and Lewy body dementia: a one-year follow-up study. Dement Geriatr Cogn Disord 2011;32:143-149.
11.
Lara E, Haro JM, Tang MX, Manly J, Stern Y: Exploring the excess mortality due to depressive symptoms in a community-based sample: The role of Alzheimer's disease. J Affect Disord 2016;202:163-170.
12.
Knoth R, Singec I, Ditter M, Pantazis G, Capetian P, Meyer RP, Horvat V, Volk B, Kempermann G: Murine features of neurogenesis in the human hippocampus across the lifespan from 0 to 100 years. PLoS One 2010;5:e8809.
13.
Spalding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB, Bostrom E, Westerlund I, Vial C, Buchholz BA, Possnert G, Mash DC, Druid H, Frisen J: Dynamics of hippocampal neurogenesis in adult humans. Cell 2013;153:1219-1227.
14.
Perry EK, Johnson M, Ekonomou A, Perry RH, Ballard C, Attems J: Neurogenic abnormalities in Alzheimer's disease differ between stages of neurogenesis and are partly related to cholinergic pathology. Neurobiol Dis 2012;47:155-162.
15.
Liu YW, Curtis MA, Gibbons HM, Mee EW, Bergin PS, Teoh HH, Connor B, Dragunow M, Faull RL: Doublecortin expression in the normal and epileptic adult human brain. Eur J Neurosci 2008;28:2254-2265.
16.
Johnson M, Ekonomou A, Hobbs C, Ballard CG, Perry RH, Perry EK: Neurogenic marker abnormalities in the hippocampus in dementia with Lewy bodies. Hippocampus 2011;21:1126-1136.
17.
Hoglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC: Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 2004;7:726-735.
18.
Ziabreva I, Ballard C, Johnson M, Larsen JP, McKeith I, Perry R, Aarsland D, Perry E: Loss of Musashi1 in Lewy body dementia associated with cholinergic deficit. Neuropath Appl Neurobiol 2007;33:586-590.
19.
Ekonomou A, Savva GM, Brayne C, Forster G, et al: Stage-specific changes in neurogenic and glial markers in Alzheimer's disease. Biol Psychiatry 2015;77:711-719.
20.
Bjoerke-Bertheussen J, Ehrt U, Rongve A, Ballard C, Aarsland D: Neuropsychiatric symptoms in mild dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 2012;34:1-6.
21.
Auning E, Rongve A, Fladby T, Booij J, Hortobagyi T, Siepel FJ, Ballard C, Aarsland D: Early and presenting symptoms of dementia with Lewy bodies. Dement Geriatr Cogn Disord 2011;32:202-208.
22.
Boldrini M, Underwood MD, Hen R, Rosoklija GB, Dwork AJ, John Mann J, Arango V: Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 2009;34:2376-2389.
23.
Lucassen PJ, Stumpel MW, Wang Q, Aronica E: Decreased numbers of progenitor cells but no response to antidepressant drugs in the hippocampus of elderly depressed patients. Neuropharmacology 2010;58:940-949.
24.
Boldrini M, Santiago AN, Hen R, Dwork AJ, Rosoklija GB, Tamir H, Arango V, John Mann J: Hippocampal granule neuron number and dentate gyrus volume in antidepressant-treated and untreated major depression. Neuropsychopharmacology 2013;38:1068-1077.
25.
Huang Y, Coupland NJ, Lebel RM, Carter R, Seres P, Wilman AH, Malykhin NV: Structural changes in hippocampal subfields in major depressive disorder: a high-field magnetic resonance imaging study. Biol Psychiatry 2013;74:62-68.
26.
McKinnon MC, Yucel K, Nazarov A, MacQueen GM: A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 2009;34:41-54.
27.
Boldrini M, Hen R, Underwood MD, Rosoklija GB, Dwork AJ, Mann JJ, Arango V: Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in major depression. Biol Psychiatry 2012;72:562-571.
28.
Jin K, Xie L, Mao XO, Greenberg DA: Alzheimer's disease drugs promote neurogenesis. Brain Res 2006;1085:183-188.
29.
Matsukawa M, Ogawa M, Nakadate K, Maeshima T, Ichitani Y, Kawai N, Okado N: Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats. Neurosci Lett 1997;230:13-16.
30.
Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R: Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-809.
31.
Anacker C, Zunszain PA, Cattaneo A, Carvalho LA, Garabedian MJ, Thuret S, Price J, Pariante CM: Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol Psychiatry 2011;16:738-750.
32.
Brunoni AR, Lopes M, Fregni F: A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008;11:1169-1180.
33.
Castren E, Voikar V, Rantamaki T: Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007;7:18-21.
34.
Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M: Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003;54:70-75.
35.
Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K: Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006;112:389-404.
36.
Muller-Thomsen T, Arlt S, Mann U, Mass R, Ganzer S: Detecting depression in Alzheimer's disease: evaluation of four different scales. Arch Clin Neuropsychol 2005;20:271-276.
37.
Banasr M, Hery M, Printemps R, Daszuta A: Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology 2004;29:450-460.
38.
Perera TD, Dwork AJ, Keegan KA, Thirumangalakudi L, Lipira CM, Joyce N, Lange C, Higley JD, Rosoklija G, Hen R, Sackeim HA, Coplan JD: Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult nonhuman primates. PLoS One 2011;6:e17600.
39.
Wang L, Zhang Z, Wang Y, Zhang R, Chopp M: Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004;35:1732-1737.
40.
Ramirez BG, Blazquez C, del Pulgar TG, Guzman N, de Ceballos MAL: Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005;25:1904-1913.
41.
Crandall J, Sakai Y, Zhang JH, Koul O, Mineur Y, Crusio WE, McCaffery P: 13-cis-retinoic acid suppresses hippocampal cell division and hippocampal-dependent learning in mice. Proc Natl Acad Sci USA 2004;101:5111-5116.
42.
Marchalant Y, Baranger K, Wenk GL, Khrestchatisky M, Rivera S: Can the benefits of cannabinoid receptor stimulation on neuroinflammation, neurogenesis and memory during normal aging be useful in AD prevention? J Neuroinflamm 2012;9:10.
43.
Aarsland D, Ballard C, Larsen JP, McKeith I: A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001;16:528-536.
44.
Ernst A, Alkass K, Bernard S, Salehpour M, Perl S, Tisdale J, Possnert G, Druid H, Frisen J: Neurogenesis in the striatum of the adult human brain. Cell 2014;156:1072-1083.
45.
Lledo PM, Alonso M, Grubb MS: Adult neurogenesis and functional plasticity in neuronal circuits. Nat Rev Neurosci 2006;7:179-193.
46.
Ming GL, Song H: Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 2011;70:687-702.
47.
Halliday GM, Song YJ, Harding AJ: Striatal beta-amyloid in dementia with Lewy bodies but not Parkinson's disease. J Neural Transm 2011;118:713-719.
48.
Hepp DH, Vergoossen DL, Huisman E, Lemstra AW, et al: Distribution and load of amyloid-beta pathology in Parkinson disease and dementia with Lewy bodies. J Neuropathol Exp Neurol 2016;75:936-945.
49.
Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, Revesz T: Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011;134:1493-1505.
50.
Walker L, McAleese KE, Thomas AJ, Johnson M, Martin-Ruiz C, Parker C, Colloby SJ, Jellinger K, Attems J: Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol 2015;129:729-748.
51.
Ruffmann C, Calboli FC, Bravi I, Gveric D, Curry LK, de Smith A, Pavlou S, Buxton JL, Blakemore AI, Takousis P, Molloy S, Piccini P, Dexter DT, Roncaroli F, Gentleman SM, Middleton LT: Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases. Neuropathol Appl Neurobiol 2016;42:436-450.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.